The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLIII. Airway involvement

XLIII.ag Obstructive airway dysfunction (see also IVc, XVx)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.i Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.o Airway fire/explosion

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.p Disordered breathing during sleep - Sleep apnea

L. Miscellaneous

L.b Chest pain (acute or subacute), lone or prominent

L. Miscellaneous

L.f Respiratory acidosis - Hypercapnia

LV. Imaging

LV.bn Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.b BAL: An excess proportion of neutrophils

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.v Path: NSIP-fibrotic pattern